NCYT.L • LSE
Unlock comprehensive alternative data signals to make better investment decisions

Track website visits, page views, unique visitors, and engagement metrics over time to gauge online interest and brand strength.

Monitor Twitter follower growth, engagement rates, and social media presence to understand brand reach and community sentiment.

Analyze TikTok follower trends and viral content performance to measure youth demographic appeal and cultural relevance.

Track Facebook page likes, comments, shares, and post engagement to assess community interaction and brand loyalty.

Monitor Instagram follower growth, engagement rates, and visual content performance across demographics.

Track YouTube channel growth, video views, and subscriber engagement to measure content marketing effectiveness.

Monitor LinkedIn company page followers and professional network growth to assess B2B brand strength and talent attraction.

Track open job positions and hiring trends as a leading indicator of company expansion, contraction, or strategic shifts.

Monitor employee headcount changes on LinkedIn to gauge organizational growth, restructuring, or cost-cutting measures.

Analyze sentiment scores from Reddit discussions to understand retail investor mood and potential price momentum.

Track daily news mentions across major publications to measure media attention, PR effectiveness, and market awareness.

View key financial metrics including Revenue, Net Income, EPS, Free Cash Flow, EBITDA, and Total Assets. Access 2-year quarterly charts for Revenue & Income and Free Cash Flow trends.

Analyze technical indicators including 50-day Simple Moving Average (SMA) with price overlay and Relative Strength Index (RSI) charts.
TrendEdge provides tools and data for research and educational purposes only and does not provide investment advice or personal recommendations.
You don't hold NCYT.L in your mock portfolio yet.
Negative EPS and a negative P/E ratio indicate that Novacyt S.A. is currently loss‑making, with no visible earnings support for the current share price. This suggests profitability challenges and likely margin pressure, even if revenue exists. Without evidence of a clear path back to sustained positive earnings, the financial profile leans structurally weak.
The stock trades at $34.60, modestly down 0.4% over the last month, but below its 200‑day moving average of $39.77, indicating a broader downtrend. An RSI of 26.38 places the stock in oversold territory, which can sometimes precede short‑term rebounds but also reflects persistent selling pressure. Overall, the technical picture suggests a weak intermediate trend with potential for a tactical bounce rather than a confirmed reversal.
Web traffic of roughly 6,470 monthly visitors and modest social media followings point to a relatively limited digital footprint, with no clear evidence of accelerating customer or investor engagement. Job openings have risen 200% month over month to 3 roles, which is directionally positive but from a very low base. Overall, alternative data is mixed and low‑intensity, offering limited support for a strong growth narrative at this stage.
Novacyt S.A. currently appears fundamentally weak due to negative earnings and the absence of clear profitability, while its stock trades below its long‑term moving average, reinforcing a downtrend despite an oversold RSI. Alternative data shows only modest engagement and small‑scale hiring, which does not yet offset the financial and technical concerns. Overall, the balance of evidence points to a cautious, bearish stance until there is a demonstrable improvement in earnings quality or growth traction.
Our AI Score rates companies on a scale from 0 to 10, based on alternative data points such as web traffic, app downloads, and job postings — combined with financial health indicators and technical signals.
Key moves vs recent baseline (last day / last week)
Plain-English summary of the biggest drivers (informational)
Potential risk factors to review
Based on earnings timing, volatility, liquidity and crowd activity. Informational signals only — not investment advice.
Reassess your thesis if any of these occur: